(S)-Thalidomide
This product is for research use only, not for human use. We do not sell to patients.
For small sizes, please check our retail website as below: www.invivochem.com
| Size | Price | Stock |
|---|---|---|
| 100mg | $1250 | Check With Us |
| 250mg | $1950 | Check With Us |
| 500mg | $2925 | Check With Us |
: Cat #: V3395 CAS #: 841-67-8 [(S)-Thalidomide]; 50-35-1 (racemic); 2098488-36-7 (Azido-Thalidomide) Purity ≥ 98%
Description: (S)-Thalidomide is the S-enantiomer of thalidomide (brand name Immunoprin) which is an immunomodulatory agent and the prototypic drug of the thalidomide class of drugs that are used mainly for the treatment of certain cancers (e.g. MM-multiple myeloma) and of a complication of leprosy.
Top Publications Citing Invivochem Products
Publications Citing InvivoChem Products
Product Promise
- Physicochemical and Storage Information
- Protocol
- Related Biological Data
- Stock Solution Preparation
- Quality Control Documentation
| Molecular Weight (MW) | 258.23 |
|---|---|
| Molecular Formula | C13H10N2O4 |
| CAS No. | 841-67-8 [(S)-Thalidomide]; 50-35-1 (racemic); 2098488-36-7 (Azido-Thalidomide) |
| Storage | -20℃ for 3 years in powder formr |
| -80℃ for 2 years in solvent | |
| Solubility In Vitro | DMSO: 52 mg/mL (201.37 mM)r |
| Water:<1 mg/mL (slightly soluble or insoluble)r | |
| Ethanol: 2 mg/mL (7.74 mM) | |
| Solubility In Vivo | 30% PEG400+0.5% Tween80+5% Propylene glycol: 5 mg/mL |
| SMILES Code | O=C1N([C@@H](CC2)C(NC2=O)=O)C(C3=C1C=CC=C3)=O |
| Synonyms | NSC 91730; NSC-91730; NSC91730; (S)-Thalidomide; l-Thalidomide; |
| Protocol | In Vitro | (S)-Thalidomide treatment increased apoptosis in a dose-dependent manner in U266 cells. (S)-Thalidomide treatment results in a reduction in cell viability in U266 cells with an IC50 of 362 μM. There are changes in the expression profile of genes involved in angiogenesis and apoptosis, but the changes are most dramatic in the apoptotic genes. In particular, the expression of I-κB kinase is decreased by two-fold, which is associated with a four-fold decrease in NF-κB expression. (S)-Thalidomide increases the Bax:Bcl-2 ratio, also increases I-kB protein levels, and decreases NF-kB activity. A dramatic decrease in Bcl-2 expression with (S)-Thalidomide suggests a possible enhancement of cytotoxic effect if combined with other cytotoxic agents. |
|---|---|---|
| In Vivo | Thalidomide does cause limb reduction defects in chick embryos as long as the embryos are directly exposed to the drug. The most useful techniques are implanting Thalidomide-soaked beads into the embryo immediately adjacent to the limb territory or soaking presumptive chick limb territories in Thalidomide and then grafting the explants to a host embryo celom. Thalidomide affects the chick limb grafted to a host embryo in a dose response fashion. Furthermore, (S)-Thalidomide is more teratogenic than (R)-Thalidomide. |
These protocols are for reference only. InvivoChem does not
independently validate these methods.
| Solvent volume to be added | Mass (the weight of a compound) | |||
|---|---|---|---|---|
| Mother liquor concentration | 1mg | 5mg | 10mg | 20mg |
| 1mM | 3.8725 mL | 19.3626 mL | 38.7252 mL | 77.4503 mL |
| 5mM | 0.7745 mL | 3.8725 mL | 7.7450 mL | 15.4901 mL |
| 10mM | 0.3873 mL | 1.9363 mL | 3.8725 mL | 7.7450 mL |
| 20mM | 0.1936 mL | 0.9681 mL | 1.9363 mL | 3.8725 mL |
The molarity calculator equation
Mass(g) = Concentration(mol/L) × Volume(L) × Molecular Weight(g/mol)
Mass
=
Concentration
×
Volume
×
Molecular Weight*
The dilution calculator equation
Concentration(start)
×
Volume(start)
=
Concentration(final)
×
Volume(final)
This equation is commonly abbreviated as: C1 V1 = C2 V2
Concentration(start)
C1
×
Volume(start)
V1
=
Concentration(final)
C2
×
Volume(final)
V2
Step One: Enter information below
Dosage mg/kg
Average weight of animals g
Dosing volume per animal µL
Number of animals
Step Two: Enter the in vivo formulation
%DMSO
+
%
+
%Tween 80
+
%ddH2O
Calculation Results:
Working concentration:
mg/ml;
Method for preparing DMSO master liquid:
mg
drug pre-dissolved in
µL
DMSO(Master liquid concentration
mg/mL)
,Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:
Take
µL
DMSO master liquid, next add
µL
PEG300, mix and clarify, next add
µL
Tween 80,mix and clarify, next add
µL
ddH2O,mix and clarify.
Note:
- (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
- (2) Be sure to add the solvent(s) in order.